{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T01:27:20Z","timestamp":1794533240557,"version":"4.9.1"},"reference-count":39,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100032703","name":"BridgeBio","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100032703","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: CardioOncology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jaccao.2026.04.006","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:32:25Z","timestamp":1781638345000},"page":"299-313","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Differential Transthyretin Stabilization in Patients With Wild Type and Variant Transthyretin Amyloidosis"],"prefix":"10.1016","volume":"8","author":[{"given":"Daniel P.","family":"Judge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan X.","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella A.","family":"Graef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Grogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prem","family":"Soman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Cappelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5074-2078","authenticated-orcid":false,"given":"Marianna","family":"Fontana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6390-6526","authenticated-orcid":false,"given":"Ahmad","family":"Masri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian D.","family":"Gillmore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5470-2257","authenticated-orcid":false,"given":"Pablo","family":"Garcia-Pavia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofan","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan C.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uma","family":"Sinha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"22","key":"10.1016\/j.jaccao.2026.04.006_bib1","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review","volume":"73","author":"Ruberg","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"10.1016\/j.jaccao.2026.04.006_bib2","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1001\/jama.2024.0442","article-title":"Cardiac amyloidosis due to transthyretin protein: a review","volume":"331","author":"Ruberg","year":"2024","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.jaccao.2026.04.006_bib3","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/nrcardio.2010.67","article-title":"Transthyretin-related amyloidoses and the heart: a clinical overview","volume":"7","author":"Rapezzi","year":"2010","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jaccao.2026.04.006_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1242815","article-title":"Hereditary transthyretin amyloidosis: a comprehensive review with a focus on peripheral neuropathy","volume":"14","author":"Poli","year":"2023","journal-title":"Front Neurol"},{"issue":"2","key":"10.1016\/j.jaccao.2026.04.006_bib5","doi-asserted-by":"crossref","first-page":"17","DOI":"10.14797\/mdcvj.1066","article-title":"ATTR epidemiology, genetics, and prognostic factors","volume":"18","author":"Obi","year":"2022","journal-title":"Methodist Debakey Cardiovasc J"},{"issue":"5","key":"10.1016\/j.jaccao.2026.04.006_bib6","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCGEN.121.003356","article-title":"Prevalence and outcomes of p.Val142Ile TTR amyloidosis cardiomyopathy: a systematic review","volume":"14","author":"Chandrashekar","year":"2021","journal-title":"Circ Genom Precis Med"},{"issue":"15","key":"10.1016\/j.jaccao.2026.04.006_bib7","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.028973","article-title":"Clinical penetrance of the transthyretin V122I variant in older Black patients with heart failure: the SCAN-MP (screening for cardiac amyloidosis with nuclear imaging in minority populations) study","volume":"12","author":"Madhani","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jaccao.2026.04.006_bib8","series-title":"Hereditary transthyretin amyloidosis","author":"Sekijima","year":"1993"},{"issue":"11","key":"10.1016\/j.jaccao.2026.04.006_bib9","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jaccao.2026.04.006_bib10","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2305434","article-title":"Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy","volume":"390","author":"Gillmore","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaccao.2026.04.006_bib11","series-title":"Vyndaqel. Prescribing information","year":"2023"},{"key":"10.1016\/j.jaccao.2026.04.006_bib12","series-title":"Attruby. Prescribing information","year":"2024"},{"issue":"24","key":"10.1016\/j.jaccao.2026.04.006_bib13","doi-asserted-by":"crossref","first-page":"9992","DOI":"10.1073\/pnas.1300761110","article-title":"AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin","volume":"110","author":"Penchala","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"17","key":"10.1016\/j.jaccao.2026.04.006_bib14","doi-asserted-by":"crossref","first-page":"7862","DOI":"10.1021\/acs.jmedchem.8b00817","article-title":"Enthalpy-driven stabilization of transthyretin by AG10 mimics a naturally occurring genetic variant that protects from transthyretin amyloidosis","volume":"61","author":"Miller","year":"2018","journal-title":"J Med Chem"},{"issue":"3","key":"10.1016\/j.jaccao.2026.04.006_bib15","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jacc.2019.03.012","article-title":"Transthyretin stabilization by AG10 in symptomatic transthyretin amyloid cardiomyopathy","volume":"74","author":"Judge","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.jaccao.2026.04.006_bib16","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/ejhf.2027","article-title":"Efficacy and safety of tafamidis doses in the tafamidis in transthyretin cardiomyopathy clinical trial (ATTR-ACT) and long-term extension study","volume":"23","author":"Damy","year":"2021","journal-title":"Eur J Heart Fail"},{"issue":"10","key":"10.1016\/j.jaccao.2026.04.006_bib17","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.jacc.2024.11.042","article-title":"Efficacy of acoramidis on all-cause mortality and cardiovascular hospitalization in transthyretin amyloid cardiomyopathy","volume":"85","author":"Judge","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.jaccao.2026.04.006_bib18","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.3390\/ijms21062075","article-title":"Undiscovered roles for transthyretin: from a transporter protein to a new therapeutic target for Alzheimer\u2019s disease","volume":"21","author":"Giao","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.jaccao.2026.04.006_bib19","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/j.bmc.2010.12.050","article-title":"A competition assay to identify amyloidogenesis inhibitors by monitoring the fluorescence emitted by the covalent attachment of a stilbene derivative to transthyretin","volume":"19","author":"Choi","year":"2011","journal-title":"Bioorg Med Chem"},{"issue":"1","key":"10.1016\/j.jaccao.2026.04.006_bib20","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/cpdd.700","article-title":"First-in-human study of AG10, a novel, oral, specific, selective, and potent transthyretin stabilizer for the treatment of transthyretin amyloidosis: a phase 1 safety, tolerability, pharmacokinetic, and pharmacodynamic study in healthy adult volunteers","volume":"9","author":"Fox","year":"2020","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"8","key":"10.1016\/j.jaccao.2026.04.006_bib22","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1016\/j.cardfail.2025.03.017","article-title":"Acoramidis for transthyretin amyloid cardiomyopathy: open-label extension study long-term follow-up","volume":"31","author":"Masri","year":"2025","journal-title":"J Card Fail"},{"issue":"4","key":"10.1016\/j.jaccao.2026.04.006_bib23","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.jaccao.2021.08.007","article-title":"Effect of tafamidis on serum transthyretin levels in non-trial patients with transthyretin amyloid cardiomyopathy","volume":"3","author":"Falk","year":"2021","journal-title":"JACC CardioOncol"},{"issue":"9","key":"10.1016\/j.jaccao.2026.04.006_bib24","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.cardfail.2019.11.024","article-title":"Stabilization of cardiac function with diflunisal in transthyretin (ATTR) cardiac amyloidosis","volume":"26","author":"Lohrmann","year":"2020","journal-title":"J Card Fail"},{"issue":"3","key":"10.1016\/j.jaccao.2026.04.006_bib25","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1080\/13506129.2022.2056011","article-title":"CSF\/plasma levels, transthyretin stabilisation and safety of multiple doses of tolcapone in subjects with hereditary ATTR amyloidosis","volume":"29","author":"Takahashi","year":"2022","journal-title":"Amyloid"},{"issue":"1","key":"10.1016\/j.jaccao.2026.04.006_bib26","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1001\/jamacardio.2025.4477","article-title":"Efficacy of acoramidis in wild type and variant transthyretin amyloid cardiomyopathy: results from ATTRibute-CM and its open-label extension","volume":"11","author":"Alexander","year":"2026","journal-title":"JAMA Cardiol"},{"issue":"9","key":"10.1016\/j.jaccao.2026.04.006_bib27","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1002\/ejhf.2589","article-title":"Prevalence and clinical outcomes of transthyretin amyloidosis: a systematic review and meta-analysis","volume":"24","author":"Antonopoulos","year":"2022","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"10.1016\/j.jaccao.2026.04.006_bib28","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1097\/FJC.0000000000001726","article-title":"Differential binding affinities and kinetics of transthyretin stabilizers","volume":"86","author":"Ji","year":"2025","journal-title":"J Cardiovasc Pharmacol"},{"issue":"24","key":"10.1016\/j.jaccao.2026.04.006_bib29","doi-asserted-by":"crossref","first-page":"9629","DOI":"10.1073\/pnas.1121005109","article-title":"Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade","volume":"109","author":"Bulawa","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"10.1016\/j.jaccao.2026.04.006_bib30","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1021\/bi500171j","article-title":"Quantification of transthyretin kinetic stability in human plasma using subunit exchange","volume":"53","author":"Rappley","year":"2014","journal-title":"Biochemistry"},{"issue":"1","key":"10.1016\/j.jaccao.2026.04.006_bib31","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1080\/13506129.2020.1808783","article-title":"Blinded potency comparison of transthyretin kinetic stabilisers by subunit exchange in human plasma","volume":"28","author":"Nelson","year":"2021","journal-title":"Amyloid"},{"issue":"2","key":"10.1016\/j.jaccao.2026.04.006_bib32","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1080\/13506129.2022.2145876","article-title":"Relationship of binding-site occupancy, transthyretin stabilisation and disease modification in patients with tafamidis-treated transthyretin amyloid cardiomyopathy","volume":"30","author":"Tess","year":"2023","journal-title":"Amyloid"},{"issue":"3","key":"10.1016\/j.jaccao.2026.04.006_bib33","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s40119-025-00422-8","article-title":"Transthyretin kinetic stabilizers for ATTR amyloidosis","volume":"14","author":"Kelly","year":"2025","journal-title":"Cardiol Ther"},{"issue":"2","key":"10.1016\/j.jaccao.2026.04.006_bib34","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.117.004000","article-title":"Use of serum transthyretin as a prognostic indicator and predictor of outcome in cardiac amyloid disease associated with wild type transthyretin","volume":"11","author":"Hanson","year":"2018","journal-title":"Circ Heart Fail"},{"issue":"6","key":"10.1016\/j.jaccao.2026.04.006_bib35","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1161\/ATVBAHA.113.301273","article-title":"Genetic stabilization of transthyretin, cerebrovascular disease, and life expectancy","volume":"33","author":"Hornstrup","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"10.1016\/j.jaccao.2026.04.006_bib36","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1001\/jamacardio.2024.4102","article-title":"Transthyretin tetramer destabilization and increased mortality in the general population","volume":"10","author":"Christoffersen","year":"2025","journal-title":"JAMA Cardiol"},{"issue":"22","key":"10.1016\/j.jaccao.2026.04.006_bib37","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1161\/CIRCULATIONAHA.122.060852","article-title":"Impact of earlier diagnosis in cardiac ATTR amyloidosis over the course of 20 years","volume":"146","author":"Ioannou","year":"2022","journal-title":"Circulation"},{"issue":"20","key":"10.1016\/j.jaccao.2026.04.006_bib38","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1016\/j.jacc.2025.03.542","article-title":"Early increase in serum transthyretin by acoramidis independently predicts improved survival in TTR amyloid cardiomyopathy","volume":"85","author":"Maurer","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jaccao.2026.04.006_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejim.2025.05.015","article-title":"Transthyretin serum levels and clinical outcomes in patients with transthyretin amyloid cardiomyopathy","volume":"142","author":"Minervini","year":"2025","journal-title":"Eur J Intern Med"},{"issue":"11 Pt 1","key":"10.1016\/j.jaccao.2026.04.006_bib40","article-title":"Serum transthyretin as prognostic biomarker for cardiovascular events and mortality: a systematic review and meta-analysis","volume":"4","author":"Terentes-Printzios","year":"2025","journal-title":"JACC Adv"}],"container-title":["JACC: CardioOncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666087326001298?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666087326001298?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T00:58:37Z","timestamp":1794531517000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666087326001298"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2666087326001298"],"URL":"https:\/\/doi.org\/10.1016\/j.jaccao.2026.04.006","relation":{},"ISSN":["2666-0873"],"issn-type":[{"value":"2666-0873","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Differential Transthyretin Stabilization in Patients With Wild Type and Variant Transthyretin Amyloidosis","name":"articletitle","label":"Article Title"},{"value":"JACC: CardioOncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaccao.2026.04.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}